--- #Pharmacy #EpilepsyAwareness #Neuropharmacology #PharmacistRole #AEDs #HealthEducation To view or add a comment, sign in Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts
the most common reported issue is injection-site reaction (redness, mild swelling, transient bruising)
LiuHTanMChengBWangSXiaoLZhuJet al
Adults 65 and older should preferably receive high-dose or adjuvanted formulations as recommended by the CDC
Therefore, the increase in ENaC expression and activity could be associated with hypertension and may cause renal damage in DKD rats
Complimentary Consult How Is BPC-157 Administered at Awaken Medical Aesthetics